MediWound Ltd. (MDWD) - What Are Analysts Thinking About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Six analysts give MediWound a consensus “Moderate Buy” rating, with four buys, one hold and one sell. The average 12-month price target is $33.00 versus the reported share price of $12.54.
• The company remains unprofitable: MediWound reported a quarterly loss of $0.77 per share, narrowly missing estimates, despite revenue of $3.09 million exceeding expectations. Analysts forecast a full-year loss of $2.37 per share.
• MediWound focuses on complex-wound therapies, led by its approved burn-treatment product NexoBrid, while developing EscharEx for chronic wounds. Insiders own 9.2% of the company, and institutional investors hold 46.83%.

Shares of MediWound Ltd. (NASDAQ:MDWD - Get Free Report) have received a consensus rating of "Moderate Buy" from the six analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $33.00.

MDWD has been the subject of a number of research reports. Wall Street Zen upgraded MediWound from a "strong sell" rating to a "sell" rating in a report on Saturday, September 26th. TD Cowen reissued a "buy" rating on shares of MediWound in a research report on Thursday, September 24th. Alliance Global Partners restated a "buy" rating on shares of MediWound in a report on Wednesday, September 16th. Weiss Ratings cut shares of MediWound from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, September 8th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a research report on Friday, August 14th.

MediWound Stock Performance

MediWound stock opened at $12.54 on Friday. MediWound has a fifty-two week low of $12.42 and a fifty-two week high of $20.03. The stock's 50 day simple moving average is $13.46 and its two-hundred day simple moving average is $14.81. The stock has a market cap of $161.14 million, a price-to-earnings ratio of -6.97 and a beta of 0.09.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. The firm had revenue of $3.09 million during the quarter, compared to the consensus estimate of $2.59 million. On average, analysts predict that MediWound will post -2.37 earnings per share for the current year.

Insider Transactions at MediWound

In related news, COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.20% of the stock is currently owned by company insiders.

Institutional Trading of MediWound

An institutional investor recently raised its position in MediWound stock. Silverberg Bernstein Capital Management LLC grew its position in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 8.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 200,005 shares of the biopharmaceutical company's stock after buying an additional 16,081 shares during the period. MediWound makes up about 1.8% of Silverberg Bernstein Capital Management LLC's investment portfolio, making the stock its 16th largest holding. Silverberg Bernstein Capital Management LLC owned about 1.56% of MediWound worth $3,222,000 at the end of the most recent reporting period. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd. NASDAQ: MDWD is a biotechnology company focused on developing and commercializing innovative therapies for complex wounds. The company's products are designed to remove damaged tissue, support wound healing and address unmet needs in burn care and chronic wounds.

MediWound's lead commercial product is NexoBrid, a topical bromelain-based enzymatic treatment used to remove eschar—the dead tissue that can form after severe thermal burns. NexoBrid has received regulatory approvals in multiple markets, including the United States, the European Union and Israel, and is marketed for use in the treatment of deep partial-thickness and full-thickness burns.

The company is also developing EscharEx, an investigational topical treatment intended to enzymatically debride chronic wounds, including venous leg ulcers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.